Theophylline action on primary human bronchial epithelial cells under proinflammatory stimuli and steroidal drugs: a therapeutic rationale approach.

Theophylline is a natural compound present in tea. Because of its property to relax smooth muscle it is used in pharmacology for the treatment of airway diseases (ie, chronic obstructive pulmonary disease, asthma). However, this effect on smooth muscle is dose dependent and it is related to the development of side effects. Recently, an increasing body of evidence suggests that theophylline, at low concentrations, also has anti-inflammatory effects related to the activation of histone deacetylases. In this study, we evaluated the effects of theophylline alone and in combination with corticosteroids on human bronchial epithelial cells under inflammatory stimuli. Theophylline administrated alone was not able to reduce growth-stimulating signaling via extracellular signal-regulated kinases activation and matrix metalloproteases release, whereas it strongly counteracts this biochemical behavior when administered in the presence of corticosteroids. These data provide scientific evidence for supporting the rationale for the pharmacological use of theophylline and corticosteroid combined drug.

Introduction

Asthma is characterized by activated mast cells, increased numbers of eosinophils, increased numbers of T helper 2 and T helper 17 lymphocytes, and increase in sensory neurogenic release.1 Allergens, some pathogens, and some diseases have been implicated in the exacerbation of asthma in both animal models and humans.2–7 Theophylline is a natural compound present in tea. Because of its property to relax smooth muscle, oral theophylline has been administered to improve the bronchoconstriction in patients with severe asthma or chronic obstructive pulmonary disease (COPD). Theophylline has dose-dependent effects, and the therapeutic index of “high dose” theophylline is narrow. Therefore, its use at “high dose” (plasma levels 10–20 mg/L) as a bronchodilator, frequently, is related with the development of side effects.8

Recently, however, preclinical studies have demonstrated that theophylline at “low dose” (plasma levels 1–5 mg/L) has anti-inflammatory effects not related to the adenosine receptor antagonism or phosphodiesterase (PDE) inhibition, which requires high dose.9 In fact, at “low dose”, theophylline inhibits phosphoinositide 3-kinase (PI3K);10 PI3K generates lipid second messengers involved in airways inflammation.11 Moreover, To et al12 documented that low concentrations of theophylline restore corticosteroid sensitivity by the enhancement of histone deacetylase (HDAC)-2 activity through inhibition of the d-isoform of PI3K and that this is independent from PDE inhibition and adenosine antagonism. In agreement with these data, Sun et al,13 in an experimental study documented that a treatment with theophylline at low dose might improve the anti-inflammatory effects of steroids by increasing HDAC-2 activity.

In patients with airways diseases, particularly with COPD, tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1 blood levels correlate with COPD severity (the higher the levels of these inflammatory stimuli the more severe is COPD expression).14

Montaño et al15 documented increased plasma levels of matrix metalloproteinases (MMP-1, MMP-7, and MMP-9) in patients with COPD, compared to healthy subjects. In agreement, more recently, Ostridge et al16 evaluating inflammatory cytokines in bronchoalveolar lavage from 24 COPD and eight control subjects documented higher levels of MMPs in lungs of subjects with COPD, suggesting that MMPs play a pivotal role in the development of COPD. Taken together, these studies documented that MMPs, ILs, and TNF-alpha may all be involved in the inflammatory pathways of COPD.

Moreover, inflammatory and structural cells, including neutrophils, macrophages, and epithelial cells, which are activated in the airways of patients with COPD release the oxidative stress that activates some transcription factors, for example, nuclear factor-κB (NF-κB) which switches on multiple inflammatory genes, resulting in amplification of the inflammatory response.17 NF-κB is regulated by complex signal transduction pathways mediated by mitogen-activated protein kinases (MAPKs). The ERK1/2 subgroup of MAPKs is activated by an MAPK named Raf (most commonly Raf-1), whose activation in turn requires the guanosine-5′-triphosphate-bound form of Ras family proteins.18 Once activated, Raf-1 phosphorylates the MAPKs MEK1 and MEK2, that finally stimulate ERK1 and ERK2. Airborne pollutants and cigarette smoke can induce the bronchial epithelium to acquire a proinflammatory phenotype, characterized by an increased production of autacoids, cytokines, and chemokines.19 Oxidant-induced phenotypic changes may thus significantly contribute to the key pathogenic role played by bronchial epithelial cells in inflammatory airway disorders (eg, asthma and COPD).

Culpitt et al20 in an in vitro study documented that the release of TNF-alpha and MMP-9 from macrophages taken from healthy subjects and normal smokers is inhibited by corticosteroids, whereas they are relatively ineffective in macrophages from patients with COPD. The reasons for resistance to corticosteroids in patients with COPD might be the marked reduction in activity of HDAC-2, which is recruited to activated inflammatory genes by glucocorticoid receptors to switch off inflammatory genes.21 The decreased activity of HDAC-2 is related to both increased secretion of cytokines (eg, TNF-alpha) and reduced response to corticosteroids.17 However, a recent finding highlights that the theophylline by itself has the capability to restore corticosteroid sensitivity.22

With this knowledge, in this study, we evaluated the effects of theophylline alone and theophylline in combination with corticosteroids on primary cultures of human bronchial epithelial cells (HBECs) under inflammatory stimuli.

Methods

Reagents

Anti-phospho-ERK1/2, Anti-phospho-NF-κB, and monoclonal antibodies were purchased from New England Biolabs (Beverly, MA, USA); an anti-(total)-ERK1/2 polyclonal antibody was commercially provided by Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). All reagents and drugs needed for cell culture, protein extraction, and Western blotting were purchased from Sigma (St Louis, MO, USA). The drugs were obtained from Sigma and then dissolved in agreement with the datasheet of each drug, in saline (0.9%) or in light-protected dimethyl sulfoxide (DMSO) as a stock solution (stored at −20°C). Stock solution was then further diluted in cell culture medium to create working concentrations. The maximum final concentration of DMSO was <0.1%.

Recombinant TNF-alpha was obtained from PeproTech, Inc. (Rocky Hill, NJ, USA). Enzyme-linked immunosorbent assay (ELISA) for MMP-2 and MMP-9 monoclonal antibody (Biotrak Human ELISA System, Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK) was performed according to manufacturer’s protocol.

Primary cultures of HBECs

Adjacent normal lung tissue from a surgical specimen of lung tumor was obtained with the written informed consent of the patients. The study was approved by the Research Ethics Committee (EUDRACT number 2010019530-27), and was carried out in accordance with the Declaration of Helsinki and Guidelines for Good Clinical Practice. To avoid contamination of tumor tissue, the normal tissue was obtained far from the tumor lesion. Therefore, HBECs were obtained from fresh surgical specimens derived from patients who underwent either lobectomy or pneumectomy, in agreement with our previous papers.23–27

The cells were then harvested and cultured in bronchial epithelial growth medium (BEGM; Clonetics, Sand Diego, CA, USA) in the presence of antibiotics (100 U/mL of penicillin and 100 µg/mL of streptomycin; Sigma) and fungizone (1 µg/mL; Gibco BRL, Gaithersburg, MD, USA). Cells were maintained at 37°C in a humidified incubator, with 5% CO2. The cell line generated by primary epithelial culture medium was referred to as HBECs.

Experimental protocol

For assays, cells at passage 3 or 4 (4 days for each passage) were seeded into 24-well cell culture plates (1 mL BEGM/well containing 5×104 cells/mL). When cells reached 70%–80% confluence, they were then treated for 24 h with TNF-alpha (50 ng/mL) or IL-1 (1 ng/mL) in the presence or absence of an overnight treatment with methylprednisone (10−5 and 10−10 M), hydrocortisone (10−5 and 10−10 M), and theophylline (10−5 M). The medium was not changed after the treatment. The solvent employed to dissolve these drugs was used as control. After this period, the medium was collected for ELISA determination and cells were processed for protein extraction and immunoblotting.

Protein extraction and immunoblot analysis

Following treatment with TNF-alpha or IL-1, cells were lysed for Western blotting in radioimmunoprecipitation assay buffer as previously reported.28–32

Briefly, protein extracts were then separated on 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Amersham Pharmacia Biotech). Immunoblotting was performed using an anti-phospho-ERK1/2 monoclonal antibody. Membranes were reprobed with a polyclonal antibody against total (phosphorylated and unphosphorylated) protein. Antibody binding was visualized by enhanced chemiluminescence-Plus (Amersham Pharmacia Biotech); intensities of experimental bands were analyzed by computer-assisted densitometry (ImageJ software for Windows) and expressed as arbitrary units (control levels set at 100). These experiments were performed in triplicate.

Enzyme-linked immunosorbent assay

A commercially available sandwich ELISA kit for MMP-2 and MMP-9 determination based on monoclonal antibody (Human Biotrak ELISA System, Amersham Pharmacia Biotech) was used to determine MMP levels, in agreement, with our previous papers.33–35 These experiments were performed in triplicate.

Statistical analysis

All data are expressed as mean ± standard error of the mean. Statistical evaluation of the results was performed by analysis of variance (ANOVA). Differences identified by ANOVA were pinpointed by paired Student’s t-test. The threshold of statistical significance was set at P<0.05.

Results

ERKs phosphorylation and NF-κB modulation under proinflammatory stimuli and steroid drugs

The exposure of HBECs for 24 h to TNF-alpha (50 ng/mL) induced a significant increase in the ERK1/2 phosphorylation (pERKs; P<0.01; Figure 1A, C, lane 2). In agreement with pERK, an increase in the activation of NF-κB (P<0.01) was recorded (Figure 1B, C, lane 2). The effect of TNF-alpha on both pERKs and NF-κB was significantly inhibited (P<0.01) by a 24-h treatment with methylprednisone and hydrocortisone at high dosage (10−5) (Figure 1A–C, lanes 3, 4). In contrast, corticosteroids at low dosage (10−10) did not modify the effects of TNF-alpha on both pERKs and NF-κB (Figures 1A–C, lanes 5, 6).

Figure 1

Effects of TNF-alpha (50 ng/mL) in the presence or absence of either methylprednisone (10−5 M) or hydrocortisone (10−10 M) in a 24-h treatment on (A) p-ERK and (B) NF-κB evaluated by (C) Western blot analysis in primary HBECs under the same treatments described in the graphs (lanes 1–6).

Notes: Theophylline is not present. Protein levels were determined by Western blot analysis. The gray level of every band was measured to check the difference in the protein expressions of HBECs by ImageJ software. Data are expressed as mean ± standard error of the mean of the three experiments. **P<0.01.

Abbreviations: HBECs, human bronchial epithelial cells; NF-κB, nuclear factor-κB; p-ERK, phosphorylated ERK 1/2; TNF, tumor necrosis factor.

The exposure of HBECs for 24 h to IL-1 (1 ng/mL) significantly increased (P<0.01) both pERK1/2 and NF-κB (Figure 2A–C, lane 2). These effects were significantly inhibited (P<0.01) by a 24-h treatment with methylprednisone and hydrocortisone at high concentrations (10−5) (Figure 2A–C, lanes 3, 4). In contrast, a 24-h treatment with methylprednisone and hydrocortisone at low concentrations (10−10) did not modify the effects of IL-1 on pERK and NF-κB (Figures 2A–C, lanes 5, 6). The treatment with theophylline (10−5) did not modify the effects of both TNF-alpha and IL-1 on p-ERK and NF-κB (Figures 3A–C, lane 2; 4A–C, lane 2), but potentiated the inhibitory effects of methylprednisone and hydrocortisone on both TNF-alpha and IL-1 (Figures 3A–C, lanes 5, 6; 4A–C, lanes 5, 6). Both TNF-alpha and IL-1 exerted their effects uniquely on phosphorylation-dependent activation of ERK1/2, without affecting its total expression (data not shown).

Figure 2

Effects of IL-1 (1 ng/mL) in the presence or absence of either methylprednisone (10−5 M) or hydrocortisone (10−10 M) in a 24-h treatment on (A) p-ERK and (B) NF-κB evaluated by (C) Western blot analysis in the primary HBECs under the same treatments described in the graphs (lanes 1–6).

Notes: Theophylline is not present. Protein levels were determined by Western blot analysis. The gray level of every band was measured to check the difference in the protein expressions of HBECs by ImageJ software. Data are expressed as mean ± standard error of the mean of the three experiments. **P<0.01.

Abbreviations: HBECs, human bronchial epithelial cells; IL-1, interleukin-1; NF-κB, nuclear factor-κB; p-ERK, phosphorylated ERK 1/2.

Figure 3

Effects of TNF-alpha (50 ng/mL) in the presence or absence of either methylprednisone (10−5 M) or hydrocortisone (10−10 M) in a 24-h treatment on (A) p-ERK and (B) NF-κB evaluated through (C) Western blot analysis in primary HBECs under the same treatments described in the graphs (lanes 1–7).

Notes: Theophylline was present at 10−5 M. Protein levels were determined by Western blot analysis. The gray level of every band was measured to check the difference in the protein expressions of HBECs by ImageJ software. Data are expressed as mean ± standard error of the mean of the three experiments. **P<0.01.

Abbreviations: HBECs, human bronchial epithelial cells; NF-κB, nuclear factor-κB; p-ERK, phosphorylated ERK 1/2; TNF, tumor necrosis factor.

Figure 4

Effects of IL-1 (1 ng/mL) in the presence or absence of either methylprednisone (10−5 M) or hydrocortisone (10−10 M) in a 24-h treatment on (A) p-ERK and (B) NF-κB evaluated through (C) Western blot analysis in primary HBECs under the same treatments described in the graphs (lanes 1–7).

Notes: Theophylline was present at 10−5 M. Protein levels were determined by Western blot analysis. The gray level of every band was measured to check the difference in the protein expressions of HBECs by ImageJ software. Data are expressed as mean ± standard error of the mean of three experiments. **P<0.01.

Abbreviations: HBECs, human bronchial epithelial cells; IL-1, interleukin-1; NF-κB, nuclear factor-κB; p-ERK, phosphorylated ERK 1/2.

Matrix metalloproteinases expression

The exposure of HBECs for 24 h to TNF-alpha (50 ng/mL) induced a significant increase (P<0.01) in MMP-2 and MMP-9 expression. These effects were reversed by a 24-h treatment with methylprednisone and hydrocortisone at high dosage (10−5); in contrast, the treatment with corticosteroids at low dosage (10−10) did not modify the effects of TNF-alpha on MMPs expression (Figure 5A and B). Similarly, IL-1 (1 ng/mL) increased the expression of MMPs and this effect was significantly reversed (P<0.01) by a 24-h treatment with corticosteroids at high dosage (Figure 6A and B). Theophylline (10−5) potentiated the effects of methylprednisone and hydrocortisone on MMP-2 and MMP-9 expression (Figures 5C and D, 6C and D).

Figure 5

Primary HBECs under TNF-alpha (50 ng/mL) stimuli in the presence or absence of either methylprednisone (10−5 M) or hydrocortisone (10−10 M) in 24-h treatment. (A) Expression of MMP-2 and (B) MMP-9 in the absence of theophylline. (C) Expression of MMP-2 and (D) MMP-9 in the presence of theophylline (10−5 M). Protein levels were determined by Western blot analysis.

Notes: The gray level of every band was measured to check the difference in the protein expressions in HBECs by ImageJ software. Data are mean ± standard error of the mean of three experiments. **P<0.01 TNF-alpha vs control. #P<0.01 (TNF-alpha with corticosteroids vs TNF-alpha without corticosteroids).

Abbreviations: HBECs, human bronchial epithelial cells; MMP, matrix metalloproteases; TNF, tumor necrosis factor.

Figure 6

Primary HBECs under IL-1 (1 ng/mL) stimuli in the presence or absence of either methylprednisone (10−5 M) or hydrocortisone (10−10 M) in a 24-h treatment. (A) MMP-2 and (B) MMP-9 expression in the absence of theophylline. (C) MMP-2 and (D) MMP-9 expression in the presence of theophylline (10−5 M). Protein levels were determined by Western blot analysis.

Notes: The gray level of every band was measured to check the difference in the protein expressions of HBECs by ImageJ software. Data are expressed as mean ± standard error of the mean of three experiments. **P<0.01 IL-1 vs control; #P<0.01 (IL-1 with corticosteroids vs IL-1 without corticosteroids).

Abbreviations: HBECs, human bronchial epithelial cells; IL-1, interleukin-1; MMP, matrix metalloproteases.

Discussion

TNF-alpha plays an important role in defense of the body against foreign pathogens such as viruses, bacteria, and fungi. TNF-alpha production within the lung (from several cells, ie, neutrophils, T cells, macrophages, monocytes, epithelial cells, fibroblasts, and smooth muscle cells) plays a central role in both inducing the expression of adhesion molecules (eg, intercellular adhesion molecule [ICAM]-1, vascular cell adhesion molecule-1, and E-selectin) and cytokines (eg, IL-1, IL-6, IL-8, platelet-derived growth factor, granulocyte macrophage colony stimulating factor, monocyte chemoattractant protein-1, and macrophage inflammatory protein 2).36

Increased levels of chemokines, cytokines, and adhesion molecules induce both the activation and recruitment of neutrophils and macrophages to the lung and lead to tissue destruction.37 In agreement, it has been documented that blood levels of TNF-alpha and IL-1 correlate with COPD severity.38,39 In this view, we treated primary HBECs with TNF-alpha and IL-1 to mimic organ conditions in COPD. In our study, both TNF-alpha and IL-1 induced a significant increase in pERK and NF-κB suggesting that these proinflammatory molecules play a role in the inflammatory process. These data are in agreement with other authors who documented that in human lung cells, TNF-alpha and IL-1beta induce the activation of NF-κB and MAPK signaling pathways.40,41

Previously in HBECs, we documented that TNF-alpha stimulates, via activation of p38 MAPK signaling pathway, IL-8 release and airway epithelial cell apoptosis, an effect that was inhibited by budesonide.42

In agreement, Ito et al43 showed both in vitro and in vivo that low-dose theophylline enhances HDAC activity in epithelial cells and macrophages via p38 MAPK activation and this effect increases the activity of corticosteroids.

Now, we have documented the involvement of ERK pathway in this mechanism. In fact in our study both methylprednisone and hydrocortisone reduced the effects of both TNF-alpha and IL-1 on both pERK and NF-κB, suggesting a suppressive effect at high concentration. In contrast, low concentration of theophylline did not counteract this effect, but significantly inhibited these mechanisms in the presence of both corticosteroids at low dosage, suggesting a synergic mechanism.

MMP-2 and MMP-9 are members of gelatinases, which start the degradation components of the endothelial basal lamina including type IV collagen, fibronectin, laminin, and heparan sulfate. In a recent clinical trial performed in patients with post-thrombotic syndrome, we documented a correlation between MMPs, TNF-alpha, and ILs suggesting that these molecules are involved in inflammatory pathways.44 Moreover, previous experimental studies documented in cerebral endothelial cells show that TNF-alpha and IL-1 beta were able to increase the MMP-9 levels and this effect was reduced by dexamethasone treatment.45,46 In agreement, in the present study, TNF-alpha and IL-1-induced MMPs release that were inhibited by methylprednisone and hydrocortisone. The effects of these corticosteroids on MMPs secretion, seems to be related to two mechanisms: 1) block of the activator protein (AP)-1 site in the MMP-9 gene, and 2) induction of the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1).46 AP-1 is involved in the coordinated expression of several genes that control inflammation, cell proliferation, and apoptosis, while TIMP-1 is the controller of MMPs.47 An imbalance between MMPs and TIMP is involved in airway diseases.48,49 Yigit et al50 documented in 27 patients with inflammatory nasal polyposis that the treatment with oral corticosteroid reduces the tissutal expression of MMP2, while increases the tissutal expression of TIMP-1. Previously, in patients with COPD as well as in patients with asthma it has been documented that a combination therapy with corticosteroid and low-dose theophylline may reduce airway inflammation, improving clinical symptoms.51,52 An explanation of this synergic mechanism has been postulated by Sun et al,13 that in an experimental study it is documented that a low-dose theophylline might improve the anti-inflammatory effects of steroids by increasing HDAC-2 activity.

In our study, theophylline used at low dosage potentiated the inhibitory effects of methylprednisone and hydrocortisone on MMP-2 and MMP-9, suggesting that theophylline may be able to improve the effects of steroids also through its anti-inflammatory activity.

Our study has several limitations. First, these data must be confirmed in clinical trials. Second, we measured the immunoreactivity of MMPs in the cells but these values are not related to the activity of the enzymes, which would have been better and more reflective of their actual enzymatic functional activity. In fact, although we used antibodies against active MMPs in this study, we did not measure activity or localize the activity. However, this study could increase the knowledge related to the synergic effects of these compounds supporting the rationale for the use of theophylline at low dosage with corticosteroid in respiratory diseases with an inflammatory component. This synergy (theophylline-corticosteroids at low dosages) resulting in improved anti-inflammatory effect, could improve the clinical efficacy of the compounds, reducing their side effects.